摘要目的 探讨齐拉西酮对精神分裂症患者糖脂代谢的影响。方法 选取2017年12月～2019年12月在我院接受治疗的120 例精神分裂症患者，按照随机数字表法分为对照组（n=60）和研究组（n=60）。对照组采用奥氮平进行治疗，研究组采用齐拉西酮进行治疗。分别测量两组在治疗前和治疗8 周后的身体质量指数（BMI）、空腹血糖（FBG）、餐后2 h 血糖（2 h BG）、空腹胰岛素（INS）、及胰岛素抵抗指数（HOMA-IR）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）、总胆固醇（TC）、三酰甘油（TG）等指标。结果 治疗前，两组BMI、FBG、2 h BG、INS、HOMA-IR、TC、TG、LDL-C、HDL-C 比较，差异无统计学意义（P＞0.05）。对照组治疗后BMI、FBG、2 h BG、INS、HOMA-IR、TC、TG、LDL-C 均高于治疗前，差异有统计学意义（P＜0.05）；对照组HDL-C 治疗前后比较，差异无统计学意义（P＞0.05）。研究组BMI、FBG、2 h BG、INS、HOMA-IR、TC、TG、LDL-C、HDL-C 治疗前后比较，差异均无统计学意义（P＞0.05）。治疗后，研究组BMI、FBG、2 h BG、HOMA-IR、INS、TC、TG、LDL-C 均低于对照组，差异具有统计学意义（P＜0.05）；治疗后两组HDL-C 比较，差异无统计学意义（P＞0.05）。结论 齐拉西酮对精神分裂症患者糖脂代谢水平无显著影响，引发患者糖尿病和糖脂代谢紊乱的可能性较小，安全性较高，具有较高的临床应用性。
Abstract：Objective To explore the effect of Ziprasidone on glucose and lipid metabolism in patients with schizophrenia. Methods A total of 120 patients with schizophrenia who were treated in our hospital from December 2017 to December 2019 were selected and divided into a control group (n=60) and a study group (n=60) according to the random number table method. In the control group, olanzapine was used for treatment, and in the study group, Ziprasidone was adopted. The body mass index (BMI), fasting blood glucose (FBG), 2 h postprandial blood glucose (2 h BG), fasting insulin (INS), insulin resistance index (HOMA-IR), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triacylglycerol (TG) of the two groups were measured before and 8-week after treatment. Results Before treatment,there were no significant differences in BMI, FBG, 2 h BG, INS, HOMAIR, TC, TG, LDL-C and HDL-C between the two groups (P＞0.05). The BMI, FBG, 2 h BG, INS, HOMA-IR, TC, TG and LDL-C of the control group were higher than those before treatment, the differences were statistically significant(P＜0.05). The difference of comparison on HDL-C before and after treatment in the control group was not statistically significant (P＞0.05). The differences in the comparisons on BMI, FBG, 2 h BG, INS, HOMA-IR, TC, TG, LDL-C and HDL-C before and after treatment in the study group were not statistically significant (P＞0.05). After treatment, the indicators of BMI, FBG, 2 h BG, INS, HOMA-IR, TC, TG and LDL-C in the study group were all lower than those in the control group, the differences were statistically significant (P＜0.05). There was no statistical difference in HDL-C between the two groups after treatment (P＞0.05). Conclusion Ziprasidone has no obvious influence on glucose and lipid metabolism in patients with schizophrenia. It is less likely to cause diabetes and glucose and lipid metabolism disorders in high safety and clinical applicability.
陈宇红. 齐拉西酮对精神分裂症患者糖脂代谢的影响[J]. 中国当代医药, 2020, 27(29): 67-69.
CHEN Yu-hong. Effect of Ziprasidone on glucose and lipid metabolism in patients with schizophrenia. 中国当代医药, 2020, 27(29): 67-69.
Mischoulon D，Shelton RC，Baer L，et al.Ziprasidone augmentation of escitalopram for major depressive disorder：cardiac，endocrine，metabolic，and motoric effects in a randomized，double-blind，placebo-controlled study[J].J Clin Psychiatry，2017，78（4）：449-455.
[18]
Park Y，Hernandez-Diaz S，Bateman BT，et al.Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes[J].Am J Psychiatry，2018，175（6）：564-574.
京公网安备 11010502046607号